Real Housewives of Beverly Hills alum Teddi Mellencamp revealed her doctor declined to prescribe GLP-1s for weight loss while she is battling stage 4 cancer.

Forbes has published a review of the top GLP-1 programs and providers of weight loss medications, highlighting various options available to consumers.

Researchers in Oklahoma have identified that the natural hormone FGF21 targets the same brain region as GLP-1 drugs and may reduce obesity by increasing metabolic rate rather than suppressing appetite.

Pfizer's GLP-1 weight loss drug is now available for pre-order in China, marking its entry into the country's market.

Amazon's One Medical has introduced a new GLP-1 weight loss management program, promising fast and convenient access to care. The program aims to provide comprehensive support for individuals seeking weight loss solutions.

Eli Lilly is capitalizing on its GLP-1 drug windfall, while Honeywell is shedding a lower-margin business unit, as part of daily market updates from the Investing Club.

A new report examines how various elements, including GLP-1 medications, male physiological factors, and lifestyle choices, contribute to and affect fertility issues.

Clinical trials for GLP-1 medications indicate an improvement in mood among users, challenging the notion of an "Ozempic personality," according to Dr. Angela Fitch.

Norwegian customs authorities reported a significant increase in the seizure of GLP-1 drugs, the active ingredient in weight loss injections, from fewer than ten in 2023 to over 6,200 last year.

Walmart is reportedly looking to increase its involvement in the GLP-1 drug phenomenon, indicating a strategic move into the market for popular weight-loss and diabetes medications.

Insurance coverage for popular GLP-1 obesity drugs is reportedly worsening, with many plans dropping or further restricting access to these blockbuster medications.

New evidence suggests that GLP-1 medications provide health benefits to individuals even if they do not experience significant weight loss, expanding the understanding of their therapeutic effects.

Jim Cramer expresses admiration for Pepsi's ability to navigate challenges in the processed food industry, particularly in the 'Year of GLP-1' drugs.

Several US states are discontinuing Medicaid coverage for GLP-1 weight-loss drugs due to rising demand and costs. This decision comes as dietitians offer advice on how to maintain adequate nutrition while using these medications.

An article outlines three distinct ways pharmacists can assist patients in maximizing their experience with GLP-1 medications, likely related to their efficacy and management.

Experts recommend incorporating strength training to help individuals preserve muscle mass when using GLP-1 medications for weight loss, addressing a common concern among users.

Research suggests that GLP-1 drugs such as Ozempic and Wegovy could potentially double the risk of divorce, a trend observed previously in bariatric surgery patients, according to expert warnings.

An overview of the rapidly growing GLP-1 market details the costs of popular weight-loss medications like Wegovy, Zepbound, and Foundayo, and offers advice on choosing the best option.

Equity research firm Bernstein estimates that apparel retailers could see an annual boost of up to $13 billion in spending as millions of people using GLP-1 drugs refresh their wardrobes due to weight loss.

Novo Nordisk has launched the high-dose version of its GLP-1 injection, Wegovy, at a price point $50 lower than Eli Lilly's competing drug, Zepbound. This strategic pricing aims to position Wegovy competitively in the market.

Applied Nutrition, a wellness brand, announced plans to introduce new products specifically designed to cater to customers using weight-loss treatments and GLP-1 jabs.

A doctor has issued a warning regarding a commonly overlooked side effect of popular GLP-1 weight loss injections, stating that these medications frequently lead to constipation.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a major supplier of GLP-1 drugs, signaling a significant corporate development for the pharmaceutical company.

A columnist discusses her conflicted feelings as body-positivity influencers she follows begin taking GLP-1 drugs, expressing a desire for them to remain 'chubby'.

VITL has successfully raised $7.5 million in funding, aiming to transform cash-pay clinic prescribing practices, particularly capitalizing on the growing popularity of GLP-1 medications.

A new study indicates that the cardiovascular benefits gained from GLP-1 medications are lost more rapidly after treatment cessation than they were acquired.

Former Playboy model Kendra Wilkinson announced her decision to start GLP-1 weight loss shots after her 40th birthday, citing tighter jeans but emphasizing her happiness and peace with the choice.

With the introduction of multiple generic variants of GLP-1-weight-loss drugs in the Indian market, concerns have emerged over their on-demand availability.

Nutritionists are offering guidance on adopting 'GLP-1 friendly' diets for individuals using GLP-1 drugs for weight management, helping to decode new marketing labels from food companies targeting this demographic.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.

Jót tehet a szívének a Wegovy, az Ozempic és a többi, GLP-1-alapú gyógyszer, de a hatás nem tart örökké, csak addig, amíg szedi őket.

Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors say Diabetes drugs could prevent anxiety and depression from worsening, according to…

BMI is just B.S. It doesn’t accurately define what it means to be overweight.

This experimental pill helped people lose about 16% of their body weight after about a year of treatment

Evidence is piling up that GLP-1 drugs can treat addiction. We must learn from the way that obesity has been stigmatised In the years since so-called weight-loss jabs entered widespread use, there…

Layla Taylor reveals her eating disorder struggle on "Mormon Wives." She weighs just 99 pounds at 5'10" and says she's unable to stop destructive patterns.

Peloton is launching a new strategy for its comeback, targeting users of GLP-1 weight-loss drugs and expanding its treadmill offerings.

LIJEKOVI GLP-1, poput Ozempica, poznati za liječenje dijabetesa i pretilosti, navodno ublažavaju simptome ADHD-a.

Companies producing sauces and spices are seeing increased deal interest, as the rise of GLP-1 weight-loss drugs is reportedly leading Americans to seek out more flavorful, 'hot stuff'.

LifeMD has outlined a target of achieving over $250 million in annualized revenue run rate by the fourth quarter of 2026, driven by record demand for GLP-1 drugs and expanded partnerships.

RESEARCH reveals that popular GLP-1 drugs used for weight loss can significantly increase the risk of osteoporosis and other bone diseases, as well as tendon ruptures.

Metabolic Balance Program is the new center in Barcelona that aims to restore GLP-1 through a multidisciplinary approach and promote conscious weight loss without rebound.

Eli Lilly has implemented artificial intelligence to significantly increase the production of its popular GLP-1 class of drugs.

China approves Pfizer GLP-1 drug for weight management  Reuters

Increasingly popular GLP-1 drugs used to treat diabetes and obesity show promise in fighting multiple substance use disorders

GoTo Foods, the parent company of brands like Cinnabon, is preparing for the 'Ozempic era' by focusing on wellness-oriented menu innovations as more consumers use GLP-1 medications.

US study suggests GLP-1s, used to treat type 2 diabetes, could also reduce risk of people already using substances from overdosing Weight loss drugs could help people avoid getting addicted to…

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and that many more would like to, but cost is a barrier.

A preliminary study suggests that GLP-1 drugs, typically used for diabetes and weight loss, could significantly reduce the need for migraine medication in individuals suffering from chronic migraines.

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

Jon Taffer says GLP-1 weight-loss medications are hurting restaurants by reducing how much customers eat and drink, making the industry challenging.

Bank of America analysts anticipate a limited impact on Eli Lilly's franchise despite Novo's recent GLP-1 price update.

Indian comedian Tanmay Bhat shared his personal experience with weight loss, revealing he lost 75 kgs without GLP-1 injections but is now experimenting with them to see their effects.

Eli Lilly's stock declined after its competitor, Novo Nordisk, announced plans to reduce the list prices for its GLP-1 class of drugs.

Bank of America advises investors to buy stock in a coffee and peanut butter maker, citing easing concerns about a previous acquisition and the company's strong position to navigate the impact of GLP-1 drugs.

Celebrity chef Gordon Ramsay criticizes restaurants for adopting Ozempic-inspired menus, calling the GLP-1-influenced dining trend 'stupid' and 'embarrassing'.

Eli Lilly and Company (LLY) stock has risen due to the expansion of Medicare coverage for GLP-1 weight loss drugs, which has alleviated pricing concerns.

McDonald's is reportedly testing a new high-protein menu in response to the growing number of consumers using GLP-1 weight-loss drugs and seeking healthier options.

Scientists from the Pomeranian Medical University in Szczecin, Poland, are cautioning that individuals using popular GLP-1 medications for obesity may be eating too little, particularly protein, leading to muscle mass loss.

US farmers are increasingly planting peas and lentils, adapting to growing consumer demand for protein-rich foods and the influence of GLP-1 weight-loss drugs on dietary habits.

Biotech investor Alex Karnal has stated that GLP-1 drugs represent a 'trillion-dollar revolution' in public health, highlighting their immense potential impact on the healthcare industry.

Amazon has introduced a new nationwide weight-loss program that incorporates GLP-1 medications, expanding its healthcare offerings.

Health insurers are raising questions about a new Medicare program that will offer GLP-1 medications to seniors for $50 per month, leading to a drop in shares for pharmaceutical companies like Novo Nordisk and Eli Lilly amid concerns over coverage plans.

The increasing popularity of GLP-1 drugs is leading cannabis dispensaries to rethink their product offerings and business strategies.

GLP-1 developer Kailera has made history by raising $625 million in a record-breaking initial public offering, with shares priced at $16 each. This significant IPO marks a major milestone for the company in the pharmaceutical sector.

Lilly's new GLP-1 pill has had a robust start on the market, recording 1,390 prescriptions in its first week.

RFK Jr.'s peptide policy could provide a growth opportunity for Hims & Hers as its GLP-1 business evolves, with an FDA review expected in 2026.

Many individuals are seeking to understand whether their insurance plans will cover GLP-1 medications, which are increasingly used for weight loss and diabetes management.

Transformative wonder drugs or overhyped sticking plasters on a much deeper problem?

GLP-1 medications like Ozempic and Mounjaro, popular for diabetes and obesity treatment, are being examined for their specific effects on the stomach and intestines.

Albertsons' stock fell after the grocery chain reported a sales miss, attributing it to slower GLP-1 growth and higher gas prices, and announced a $774 million settlement for opioid-related claims.

New evidence suggests that GLP-1 medications, while primarily known for weight loss, are providing health benefits to users even if they don't experience significant weight reduction. This indicates a broader therapeutic potential for these drugs.

A new study, based on an analysis of Reddit posts, has found that users of GLP-1 weight-loss medications reported side effects such as fatigue, chills, and menstrual irregularities that were not observed in clinical trials.

A new study reveals common errors among patients taking GLP-1 medications like Ozempic, including skipping meals and low caloric intake, which can lead to severe deficiencies such as sarcopenia without proper nutritional guidance.

New research indicates that individual genetic variations play a significant role in determining the effectiveness of GLP-1 drugs for weight loss and the likelihood of experiencing their side effects.

Eli Lilly is losing market share in India's GLP-1 market due to the influx of cheap semaglutide generics, while Novo Nordisk maintains its position through price cuts for Ozempic and Wegovy.

Flowers Foods (FLO) is experiencing business pressure due to the rising popularity of GLP-1 weight-loss treatments and a general softening of consumer sentiment, impacting its financial outlook.

JW Pharmaceutical has announced an $81 million licensing agreement with China’s Gan & Lee Pharmaceuticals, securing exclusive domestic rights to bofanglutide, a next-generation GLP-1 receptor agonist. The Korean company will lead the development of the drug in the domestic market.

Bank of America has lowered its price target for McKesson (MCK), citing concerns over pricing pressure related to GLP-1 drugs. This adjustment reflects potential challenges for the healthcare company in the current market.

Novo Nordisk's new Wegovy pill has seen an explosive launch, drawing a new wave of patients into GLP-1 weight loss treatments. CNBC interviewed five U.S. patients who shared their varying initial experiences with the drug following its introduction.

Medpace Holdings (MEDP) has reportedly seen benefits from the strong performance and demand within the GLP-1 drug market.

Eli Lilly's new GLP-1 weight-loss pill, Foundayo, which is the first oral GLP-1 not requiring fasting, has been approved by the Food and Drug Administration and has shown effectiveness in clinical trials, with one user losing 25 pounds.

An analysis has identified five biotech companies that could become significant acquisition targets in the GLP-1 drug market.

The CEO of Mars has been appointed to a board role at Novo Nordisk, a key supplier of GLP-1 drugs.

Beyond their success as weight loss medications, GLP-1 drugs are now being investigated for their potential to help mitigate the opioid crisis, which claims over 100,000 lives annually from overdoses.

Individuals considering GLP-1 pills for weight loss are advised to review eight key pieces of information before beginning treatment, covering important aspects of these medications.

A report highlights that GLP-1 therapy, while effective for appetite suppression, may put Indian patients at risk of nutrient deficiency, advising on necessary precautions.

A new drug approval for Novo Nordisk is being discussed as a potential game-changer that could significantly impact the company's competitive position in the GLP-1 market.

The government (presumably India) is increasing its scrutiny of GLP-1 weight-loss drugs amidst growing concerns over their unauthorized sales and distribution.

Scientists have identified concerning effects that occur when individuals cease taking GLP-1 medications.

GLP-1 drugs, while offering significant therapeutic advancements, are also susceptible to misuse, raising concerns about their broader implications beyond intended medical applications.

Istraživači su pronašli zmijski metabolit koji uspešno suzbija apetit kod gojaznih miševa, bez neželjenih efekata zabeleženih kod lekova GLP-1.

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.

American restaurant chains are reconsidering both menus and portion sizes after the use of so-called GLP-1 drugs, such as Ozempic, Wegovy, and Zepbound, has increased significantly.

The evidence is tantalising. But that is not the same as proof

Vânzările de ciocolată cresc mai rapid în rândul utilizatorilor din Statele Unite ai medicamentelor pentru slăbit din clasa GLP-1 decât în restul populației, a declarat marți producătorul elvețian de…

In recent years, a class of drugs primarily used for diabetes, now famous GLP-1 drugs due to their effectiveness against obesity, have been found to...

New study suggests GLP-1 drugs like Ozempic and Wegovy may raise fracture risk by 11% in adults 65 and older with type 2 diabetes compared to other diabetes medications.

Omada Health has outlined a target of 22% revenue growth by 2026 and is launching new GLP-1 and cholesterol management programs.

There is growing evidence that popular weight loss drugs (GLP-1) like Ozempic also have potential in treating addiction to alcohol, nicotine, and drugs. Results from new clinical studies are expected.

Argus adopts a bullish stance on Pfizer, emphasizing the company's GLP-1 and oncology pipeline developments.

GLP-1 Drugs Tied to Fewer Addictions, Overdoses in Large Study  Bloomberg.com

An obesity meet in Chennai, India, brought together doctors, nutritionists, and coaches to discuss approaches beyond GLP-1 weight-loss drugs like Ozempic. The event focused on promoting strength training and science-backed diets to combat rising obesity rates and dismantle the stigma around 'celebrity jabs'.

Hims' expansion efforts may not materialize quickly enough to capitalize on the growing but risky GLP-1 weight-loss drug market.

New research indicates that GLP-1 weight-loss drugs can affect sexual function, with a significant percentage of users reporting changes in their sex lives.

JPMorgan forecasts a significant increase in direct-to-consumer sales for obesity drugs, identifying Eli Lilly as the primary beneficiary due to its 'best-in-class' GLP-1 status.

The Mayrlife clinic in Aussee celebrates its 10th anniversary, highlighting its F. X. Mayr fasting program and its approach to GLP-1 medications like Ozempic.

Barclays suggests buying a best-in-class GLP-1 leader, projecting a 32% upside despite increasing competition in the market.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

Australian researchers are cautioning that popular GLP-1 weight-loss drugs may lead to scurvy, a historic 'pirate disease,' due to potential poor nutrition and vitamin C deficiency.

Scientists have identified a minimally invasive endoscopic procedure, described as a "metabolic reset," that may help prevent weight rebound in individuals who stop taking GLP-1 drugs. This method could offer lasting weight loss maintenance.

Lexaria Bioscience has successfully identified and secured its niche within the highly profitable GLP-1 market, as reported by The Globe and Mail.

Amazon has introduced a new GLP-1 program, prompting discussions and inquiries into whether the initiative will result in cost savings for consumers.

Amazon.com is set to offer a new program focused on GLP-1 weight-loss drugs, according to the Wall Street Journal.

Pfizer is exploring a monthly weight loss shot that could potentially disrupt the current GLP-1 market, currently dominated by Lilly and Novo Nordisk.

The article discusses whether Eli Lilly's new GLP-1 pill could drive the company's stock valuation back to the $1 trillion mark, examining its market potential.

Eli Lilly's CEO has voiced disappointment that only a small fraction of Americans are currently using GLP-1 medications, a class of drugs used for conditions like diabetes and weight loss. The statement highlights concerns about the accessibility or uptake of these treatments.

The UAE has become one of the first countries to approve Eli Lilly's once-daily oral obesity pill, Foundayo (orforglipron), a GLP-1 receptor agonist that mimics natural hormones to regulate appetite.

Experts have identified five specific supplements that individuals should avoid when they are taking GLP-1 medications, such as those used for weight loss and diabetes.

A study published in Nature identified a specific genetic variant that may enhance the effectiveness of GLP-1 weight-loss drugs such as semaglutide and tirzepatide.

China is poised to initiate a price war for weight-loss drugs, particularly GLP-1 related treatments like semaglutide, as key patents begin to expire and the country's pharmaceutical industry can produce these treatments at scale.

A significant number of individuals who start GLP-1 medicines for obesity and diabetes later quit them but plan to restart, a practice not currently recommended due to unknown long-term health impacts.

An article explores the benefits and myths surrounding berberine, a supplement often dubbed 'natural Ozempic,' clarifying that while it offers some advantages, it is not comparable to GLP-1-based medications.

Scientists have discovered that GLP-1 analogs, popular drugs for treating type 2 diabetes, do not have the same effect on all patients. Genetic factors may be responsible for why semaglutide-containing preparations are less effective for some individuals.

The family behind Tapito, an iconic LA hot sauce, decided to sell their business due to a surge in demand for hot sauce and other condiments, attributed to the growing use of weight-loss drugs like GLP-1s.

The surging use of GLP-1 drugs is generating significant economic opportunities and creating "winners" in various industries, extending far beyond the pharmaceutical sector.

Eli Lilly has taken the lead in the obesity drug race against Novo Nordisk, whose GLP-1 pill momentum is now facing a pricing test, according to a leading bank.

Doctors are issuing a warning about a specific symptom that may manifest months after individuals begin taking GLP-1 weight loss medications.

A study observing 600,000 veterans found that those treated with GLP-1 medication for weight loss showed a reduced risk of addiction. The findings suggest a potential new application for these drugs.

The price target for Hims & Hers has been reduced, reportedly due to the company's transition related to GLP-1 medications.

Ulta Beauty CEO Kecia Steelman stated that the popularity of GLP-1 weight loss drugs has led to a new demand for specific hair and skincare products, as users seek to counteract the drugs' side effects.

As prescriptions for GLP-1 drugs have increased, doctors are reporting thirteen unexpected benefits beyond blood sugar control and weight management. However, despite their growing use, these medications are not without risks.

The Indian government has issued a detailed advisory and increased regulatory surveillance on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision due to rising demand and flagged risks.

Canadian experts are weighing in on U.S. civil cases that expose how social media addiction negatively impacts youth, with an Indian news summary also highlighting the ongoing social media addiction trials.

Eli Lilly (LLY) has seen gains driven by the strong performance and growth of its GLP-1 franchises drugs.

Former Playboy model Kendra Wilkinson has openly discussed her decision to begin GLP-1 medication for weight management, sharing insights into her lifestyle choice after turning 40.

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular risk by 22%, a new study finds.

Doctors specializing in obesity have responded to Polish singer Dorota Rabczewska (Doda), who controversially labeled individuals using GLP-1 drugs for obesity as "lazy" and "fat," claiming they choose a shortcut.

Nutrition experts are cautioning that the increasing popularity of high-protein diets, often coupled with GLP-1 drugs and low-carb eating, is causing a significant fiber deficiency among Americans.

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

Scientists have discovered a molecule in python blood that suppresses appetite in obese mice without the typical side effects of GLP-1 drugs, potentially paving the way for new obesity treatments.

New research challenges fears about Ozempic weight regain. Cleveland Clinic study of 8,000 patients finds minimal rebound after stopping GLP-1 medications.

If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.

A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in premium chocolate sales, even as some research shows overall food spending…

Die sogenannten GLP-1-Analoga haben die Behandlung von Übergewicht und Diabetes revolutioniert. Laut neuen Studien profitieren Frauen noch stärker, was am Gehirn liegen dürfte

A large study found that people taking GLP-1 drugs like Ozempic for diabetes were less likely to be diagnosed with substance use disorder.

Amazon Pharmacy is expanding its range of GLP-1 medications by adding the Zepbound KwikPen to its offerings.

Oprah Winfrey stuns at Paris Fashion Week with dramatic weight loss. The media mogul previously opened up about her journey with GLP-1 medication and obesity.

Hims & Hers stock experienced a significant 40% surge following a 'GLP-1 truce'.

Τα τελευταία χρόνια, λίγες κατηγορίες φαρμάκων έχουν προκαλέσει τόσο μεγάλο ενδιαφέρον όσο οι θεραπείες που βασίζονται στην ορμόνη GLP-1.

A large study of data from Veterans Affairs finds that people on GLP-1 drugs were less likely to develop substance abuse disorder or overdose.

New research suggests that drugs designed to treat diabetes and obesity, known as GLP-1 agonists, may also reduce the level of established addiction and the risk of overdose.

Study shows that GLP-1 medications reduce the risk of addiction.

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.

Savannah Chrisley's prescription weight loss website is under a federal microscope ... 'cause the FDA warned her about making false and misleading claims about GLP-1s.

New research, based on animal model trials in the UK, suggests that GLP-1 weight-loss drugs could prevent 'no-reflow' complications in heart attack recovery, potentially saving lives.

My day at Delmonico's included potatoes in various forms: raw, mashed, and fried. Alice Tecotzky I spent a day at Delmonico's, a classic Wall Street steakhouse, as the team got ready for lunch. I saw how RTO and the latest iteration of office perks have transformed Wall Street's lunch culture. Though GLP-1s have swept the finance world, Delmonico's hasn't seen much of an impact. A few weeks ago, I, someone who generally abstains from beef but is committed to understanding the modern power l...

Eli Lilly is preparing to release orforglipron, a new once-daily GLP-1 pill, which has shown an average of 15-20 pounds of weight loss in clinical trials for people with diabetes.

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

The cuts aim to make the drugs more accessible to insured patients, particularly people with high-deductible health plans or co-insurance benefit designs.

GLP-1 drugs for weight loss are growing in popularity in the U.S. and across the world. Here's what some users say about their experiences with the medicines.

FDA chief Marty Makary addresses the contentious period for the agency, marked by significant staff and budget cuts, and discusses changes to vaccine policy and the use of compounded GLP-1s.

Hims & Hers' strategy involving GLP-1 pills has reportedly backfired, leading to increased scrutiny and a crackdown on drug compounders.

The initial excitement surrounding GLP-1 weight loss drugs provides insights into current market dynamics, with connections drawn to jet fuel and software sell-offs.

The manufacturing process for GLP-1 medications, a class of drugs used for weight loss and diabetes, is being scrutinized for its significant environmental impact.